<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04117555</url>
  </required_header>
  <id_info>
    <org_study_id>5956-19</org_study_id>
    <nct_id>NCT04117555</nct_id>
  </id_info>
  <brief_title>Assessment of Pupil Light Responses in Patients With Parkinson Disease</brief_title>
  <official_title>Assessment of Pupil Light Reflex in Patients With Parkinson Disease in Comparison to Healthy Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Parkinson diseases (PD) is the second most common degenerative disease of the central nervous
      system. The development of early diagnostic biomarkers may help identify at-risk individuals
      and allow precocious interventions at the onset of disease and more precise monitoring of
      therapies that may slow disease progression.

      Proof of concept studies indicated significant differences in pupil light response between PD
      patients and healthy controls. The feasibility of using pupillometry for assesment of PD will
      be examined.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pupillometry</measure>
    <time_frame>1 day</time_frame>
    <description>Pupil response to light stimuli</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best corrected visual acuity</measure>
    <time_frame>1day</time_frame>
    <description>Visual Acuity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Color vision</measure>
    <time_frame>1 day</time_frame>
    <description>Color vision by Farnsworth/Lanthon D-15 Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Humphrey 24-2 perimetry</measure>
    <time_frame>1 day</time_frame>
    <description>Visual field will be assessed by Humphrey 24-2 perimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spcetral Domain Optical Coherence Tomography (SD-OCT)</measure>
    <time_frame>1 day</time_frame>
    <description>Optic nerve and retinal structure will be assessed by SD-OCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual evoked potential</measure>
    <time_frame>1 day</time_frame>
    <description>Occipital cortex function will be assessed by visual evoked potential (VEP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Pupillometry at 1 year</measure>
    <time_frame>Single visit: 1 day, 1 year after baseline testing</time_frame>
    <description>Change from baseline in pupil response to light stimuli at 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline best corrected visual acuity at 1 year</measure>
    <time_frame>Single visit: 1 day, 1 year after baseline testing</time_frame>
    <description>Change from baseline visual acuity at 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline color vision at 1 year</measure>
    <time_frame>Single visit: 1 day, 1 year after baseline testing</time_frame>
    <description>Change from baseline color vision by Farnsworth/Lanthon D-15 at 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Humphrey 24-2 at 1 year</measure>
    <time_frame>Single visit: 1 day, 1 year after baseline testing</time_frame>
    <description>Change from baseline Humphrey 24-2 visual field at 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline SD-OCT at 1 year</measure>
    <time_frame>Single visit: 1 day, 1 year after baseline testing</time_frame>
    <description>Change from baseline optic nerve and retinal structure by SD-OCTat 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline visual evoked potential at 1 year</measure>
    <time_frame>Single visit: 1 day, 1 year after baseline testing</time_frame>
    <description>Change from baseline occipital cortex function by visual evoked potential testing to at 1 year</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Diagnostic Test: Pupillometry</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Parkinson patients</arm_group_label>
    <description>Diagnostic Test: Pupillometry</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Pupil response to light stimuli</intervention_name>
    <description>Objective and accurate measurement of pupillary responses to light stimuli</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Parkinson patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        One hundred Parkinson patients or patients with parkinsonism and 100 age-matched controls
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  General inclusion criteria

               1. Age 30-75 years old

               2. Signed written informed consent

               3. Gender: Both (Male and Female)

               4. Pupillary reflex to light.

               5. Clear ocular media

        Patients' Inclusion Criteria:

        Patients with clinical presentations of the neurodegenerative forms of parkinsonism
        (bradykinesia, extrapyramidal rigidity, tremor, postural instability and gait disturbance)
        including: idiopathic Parkinson disease (PD), Lewy body disease (LBD), progressive
        supranuclear palsy (PSP), multiple system atrophy (MSA), corticobasal degeneration (CBD)
        and secondary parkinsonisms.

        Control group- inclusion criteria

          1. Normal eye examination

          2. Best-corrected visual acuity (BCVA) of 20/20

          3. Normal color vision test (Farnsworth/Lanthon D-15 Test)

          4. No present ocular disease

          5. No past ocular disease or surgery within last 6 months

          6. No use of any topical or systemic medications that could adversely influence efferent
             pupil movements

          7. Normal 24-2 Humphrey visual field and

               -  Short duration (â‰¤10 minutes)

               -  Minimal fixation losses, False positive errors and False negative errors (less
                  than 30% for each one of reliability indices)

        Exclusion Criteria:

          1. Diagnosis of dementia.

          2. Cognitive decline that may impair obtaining informed consent.

          3. Tremor or dyskinesia that could interfere with ophthalmic evaluation

          4. History of past (last 3 months) or present ocular disease or ocular surgery

          5. Use of any topical or systemic medications that could adversely influence pupillary
             reflex

          6. Psychiatric illness, active psychosis.

          7. Previous neurosurgical interventions, including stereotactic neurosurgical procedures.

          8. Past or current strokes or brain injury and other brain disorders (except
             PD/parkinsonism for patient group)

          9. Anti-dopaminergic drugs.

         10. Intolerance to gonioscopy, slit lamp examination, Goldmann applanation tomometry or
             other schedule study procedure.

         11. Visual media opacity including cloudy corneas.

         12. Any condition preventing accurate measurement or examination of the pupil.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Sharon Hassin-Baer, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheba Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lori Gueta</last_name>
    <phone>972527485888</phone>
    <email>Lori.Gueta@sheba.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Goldschleger Eye Research Institute, Sheba Medical Center,</name>
      <address>
        <city>Tel HaShomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>September 18, 2019</study_first_submitted>
  <study_first_submitted_qc>October 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 7, 2019</study_first_posted>
  <last_update_submitted>October 3, 2019</last_update_submitted>
  <last_update_submitted_qc>October 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sheba Medical Center</investigator_affiliation>
    <investigator_full_name>Dr. Sharon Hassin</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

